Loading patent…
AssigneeThe Board of Trustees of the Leland Stanford Junior University
InventorsRoy Louis Maute, Kipp Andrew Weiskopf, Aaron Michael Ring, Irving L. Weissman
Estimating the term…
Methods and compositions are provided for inducing phagocytosis of a target cell, treating an individual having cancer, treating an individual having an intracellular pathogen infection (e.g., a chronic infection), and/or reducing the number of inflicted cells (e.g., cancer cells, cells infected with an intracellular pathogen, etc.) in an individual. Methods and compositions are also provided for predicting whether an individual is resistant (or susceptible) to treatment with an anti-CD47/SIRPA agent. In some cases, the subject methods and compositions include an anti-MHC Class I/LILRB1 agent. In some cases, the subject methods and compositions include an anti-MHC Class I/LILRB1 agent and an anti-CD47/SIRPA agent (e.g., co-administration of an anti-MHC Class I/LILRB1 agent and an anti-CD47/SIRPA agent). Kits are also provided for practicing the methods of the disclosure.
A composition for increasing phagocytosis of a target cell, the composition comprising:
A kit for increasing phagocytosis of a target cell, the kit comprising:
A method of inducing phagocytosis of a target cell, the method comprising:
A method of treating an individual having cancer or having an intracellular pathogen infection, the method comprising
A method of predicting whether an individual is resistant or susceptible to treatment with an anti-CD47/SIRPA agent, the method comprising:
An anti-MHC ClassI/LILRB1 agent, wherein said agent is a polypeptide comprising the light chain CDR amino acid sequences set forth in SEQ ID NOs:
Dependencies are inferred from the claim text.